Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $27.4 million.

  • Keros Therapeutics' Total Current Liabilities fell 16.94% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year decrease of 16.94%. This contributed to the annual value of $27.4 million for FY2024, which is 12.62% up from last year.
  • As of FY2024, Keros Therapeutics' Total Current Liabilities stood at $27.4 million, which was up 12.62% from $24.4 million recorded in FY2023.
  • In the past 5 years, Keros Therapeutics' Total Current Liabilities ranged from a high of $27.4 million in FY2024 and a low of $7.2 million during FY2020.
  • In the last 3 years, Keros Therapeutics' Total Current Liabilities had a median value of $24.4 million in 2023 and averaged $22.8 million.
  • Data for Keros Therapeutics' Total Current Liabilities shows a peak YoY surged of 64.89% (in 2021) over the last 5 years.
  • Over the past 5 years, Keros Therapeutics' Total Current Liabilities (Yearly) stood at $7.2 million in 2020, then spiked by 64.89% to $11.8 million in 2021, then surged by 39.68% to $16.5 million in 2022, then skyrocketed by 47.30% to $24.4 million in 2023, then rose by 12.62% to $27.4 million in 2024.